Udo Johannes Vetter

ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.

RV Invest GmbH provides business and economic services. The private company is based in Ravensburg, Germany. The CEOs are Udo Johannes Vetter, Gunther Strothe, Wolfgang Kerkhoff. The German company was founded in 2016.

ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011.

ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.

ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011.

ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.

ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011.

OncoBeta GmbH is a privately held medical device company based in Garching near Munich, Germany. The German company specializes in the development and commercialization of innovative therapies, particularly the epidermal radioisotope therapy Rhenium-SCT® for non-melanoma skin cancers and keloid scars. OncoBeta was founded in 2010 by Oliver Buck and Doris Zur Muehlen, and the CEO is Shannon D. Brown.

OncoBeta GmbH is a privately held medical device company based in Garching near Munich, Germany. The German company specializes in the development and commercialization of innovative therapies, particularly the epidermal radioisotope therapy Rhenium-SCT® for non-melanoma skin cancers and keloid scars. OncoBeta was founded in 2010 by Oliver Buck and Doris Zur Muehlen, and the CEO is Shannon D. Brown.

For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world.

RV Invest GmbH provides business and economic services. The private company is based in Ravensburg, Germany. The CEOs are Udo Johannes Vetter, Gunther Strothe, Wolfgang Kerkhoff. The German company was founded in 2016.

For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world.

ITM Isotopen Technologien München AG develops diagnostic and therapeutic radionuclides and radiopharmaceuticals. Its products include EnolucinBeta, 188w/188re generator, 255AC/213Bi Generator, IQS-TS, IQS, consumables, and GMP Radiolabeling service. The company was founded in 2004 and is headquartered in Garching, Germany.

For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world.

For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world.

For more than 25 years, Vetter Pharma-Fertigung has been synonymous with high quality aseptically pre-filled application systems. As a strategic partner, the company supports clients from the pharmaceutical and biotechnology industries in every phase of production, from product development through to successful product launches and commercial manufacturing. The firm is an independent company without any pharmaceutical products on the market. This means it can guarantee its partners absolute loyalty - as a conflict of interests is impossible right from the start. The company is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, Germany, Vetter also produces its own injection systems, such as the Vetter Lyo-Ject® dual-chamber syringe. The company employs about 1,900 people world-wide and holds nearly 140 patents. Vetter boasts longstanding experience in handling client products and processes approved by the FDA, the EMEA and other authorities. Vetter Development Service provides support for its pharmaceutical and biotech clients in the early stages of development, from clinical phases and regulatory approval to worldwide product launch. Vetter Commercial Manufacturing handles the entire production process, from compounding and aseptic filling to the final packaging of a product. Vetter Solutions' patented application systems enable clients to compete more effectively throughout the world.

ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011.

ITM Isotope Technologies Munich SE is a German radiopharmaceutical biotech company that specializes in providing precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians, and partners. ITM Isotope Technologies Munich is based in Garching, DE, and has subsidiaries in Germany. The company aims to provide a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. ITM has a broad precision oncology pipeline, including two phase III studies, combining the company's high-quality radioisotopes with a range of targeting molecules. The company benefits from its GMP infrastructure and expertise in sourcing, processing, and radiolabeling. The company was founded in 2004, and Steffen Schuster has been the CEO of the company since 2011.